Page last updated: 2024-08-02 10:52:51
tafluposide
Description
tafluposide: structure in first source [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 9877073 |
| CHEMBL ID | 3989413 |
| SCHEMBL ID | 26426 |
| MeSH ID | M0577431 |
Synonyms (15)
| Synonym |
|---|
| tafluposide [inn] |
| unii-qn043x3zdw |
| f 11782 |
| tafluposide |
| 4-((5r,5ar,8ar,9s)-9-((4,6-o-((1r)-ethylidene)-2,3-biso-((pentafluorophenoxy)acetyl)-beta-d-glucopyranosyl)oxy)-6-oxo-5,5a,6,8,8a,9-hexahydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-5-yl)-2,6-dimethoxyphenyle dihydrogen phosphate |
| f-11782 |
| 179067-42-6 |
| qn043x3zdw , |
| SCHEMBL26426 |
| 4-((5r,5ar,8ar,9s)-9-((4,6-o-((1r)-ethylidene)-2,3-bis-o-((pentafluorophenoxy)acetyl)-.beta.-d-glucopyranosyl)oxy)-6-oxo-5,5a,6,8,8a,9-hexahydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-5-yl)-2,6-dimethoxyphenyl dihydrogen phosphate |
| DTXSID50170767 |
| [(2r,4ar,6r,7r,8s,8ar)-6-[[(5s,5ar,8ar,9r)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]d |
| CHEMBL3989413 |
| Q27287346 |
| AKOS040749605 |
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 10, Issue:9, 2004
Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer.Anti-cancer drugs, , Volume: 14, Issue:6, 2003
Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.Cancer chemotherapy and pharmacology, , Volume: 49, Issue:6, 2002
In vivo antitumor activity of F 11782, a non-intercalating dual catalytic inhibitor of topoisomerases I and II, against a panel of human tumor xenografts.Journal of experimental therapeutics & oncology, , Volume: 2, Issue:4
Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 10, Issue:9, 2004
Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer.Anti-cancer drugs, , Volume: 14, Issue:6, 2003
Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II.Biochemical pharmacology, , Mar-01, Volume: 65, Issue:5, 2003
Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.Anti-cancer drugs, , Volume: 11, Issue:10, 2000
Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases.British journal of cancer, , Volume: 83, Issue:11, 2000
F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.Cancer chemotherapy and pharmacology, , Volume: 46, Issue:2, 2000
Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II.Anticancer research, , Volume: 20, Issue:6B
Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.Anti-cancer drugs, , Volume: 11, Issue:10, 2000
Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases.British journal of cancer, , Volume: 83, Issue:11, 2000
F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.Cancer chemotherapy and pharmacology, , Volume: 46, Issue:2, 2000
Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.Cancer chemotherapy and pharmacology, , Volume: 49, Issue:6, 2002
In vivo antitumor activity of F 11782, a non-intercalating dual catalytic inhibitor of topoisomerases I and II, against a panel of human tumor xenografts.Journal of experimental therapeutics & oncology, , Volume: 2, Issue:4
Interactions (1)